This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention relates to a novel quercetin derivative compound and to a use thereof. More specifically, the present invention relates to a novel quercetin derivative compound having inhibitory activity against bromodomain extra-terminal (BET) proteins, and to a pharmaceutical composition for preventing or treating BET protein-related diseases, comprising the same.

The present disclosure relates to compositions, methods, and uses for using an isolated anti-FcRn antibody or an antigen-binding fragment thereof that binds to neonatal Fc receptor (FcRn) to prevent, modulate, or treat warm autoimmune hemolytic anemia.

The present disclosure relates to compositions, methods, and uses for using an isolated anti-FcRn antibody or an antigen-binding fragment thereof that binds to neonatal Fc receptor (FcRn) to prevent, modulate, or treat warm autoimmune hemolytic anemia.

Disclosed are methods of treating an individual, for example, a human individual, or more particularly a pediatric individual, having a disease characterized by liver fibrosis, comprising administering a therapeutically effective amount of one or both of a Complement Factor B inhibitor and a Complement Factor P (“CFP” or “properdin”) inhibitor, e.g., anti-CFP antibody and/or anti-CFB antibody or the respective antigen-binding fragment(s) thereof. Exemplary disease states include, but are not limited to, biliary atresia and post-Kasai biliary atresia.

This disclosure features compositions comprising niclosamide for use in treating one or more conditions (or one or more symptoms thereof) characterized by an abnormal inflammatory response in one or more particular subject (e.g., patient) populations in need thereof. Such conditions include, e.g., an autoimmune disorder, e.g., colitis, e.g., autoimmune colitis, e.g, an inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis. In some embodiments, the uses include rectally (e.g., via enema) administering niclosamide.

The present invention relates to a novel compound represented by Formula 1, functioning as a sphingosine-1-phosphate receptor agonist useful for treating autoimmune disorders, a preparation method therefor, a pharmaceutical composition containing the same as an active ingredient, and a use. The compound according to the present invention has an effect in extensive autoimmune diseases and chronic inflammatory diseases, including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulatory disorders.

The present invention relates to a composition, comprising: IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α, for promoting immunomodulatory activity and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory activity and inflammation-modulating ability by using same. When treated with IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α according to the present invention, stem cells are induced to increase IFN-γ inhibition, inducible costimulatory ligand (ICOSL) expression, indoleamine 2,3-dioxygenase (IDO) expression, and Galectin 1 expression, and thus can find various applications in a variety of immune disease treatment fields using stem cells.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.

Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.